Drug-resistant tuberculosis (DR-TB), also known as TB RO (Resistant Obat), occurs when Mycobacterium tuberculosis no longer responds to standard first-line drugs such as isoniazid and rifampicin. This form of TB requires longer, more complex, and more expensive treatment, often lasting up to two years. In regions like Papua, where healthcare access and monitoring remain challenging, treatment success rates lag behind national and global targets.
A Growing Public Health Challenge
Indonesia is among the countries with the highest burden of drug-resistant tuberculosis globally. National data show that treatment success rates for DR-TB remain below the 90 percent target set by health authorities. In Papua Province, the situation is particularly concerning, with past reports showing success rates as low as 33 percent.
This context underscores the importance of the study conducted by Yulpriati Kalua, Hasmi, Sarce Makaba, Arius Togodly, Novita Medyati, and RoRosmin Mariati Tingginehe all affiliated with Cenderawasih University. Their work provides one of the most comprehensive analyses to date of why DR-TB treatment fails in eastern Indonesia.
Study Design and Data Analysis
The research analyzed 471 patients diagnosed with drug-resistant tuberculosis who completed treatment between 2022 and 2024 in Papua Province. Using a cross-sectional observational design, the team examined secondary health data to identify patterns and risk factors associated with treatment outcomes.
The analysis combined descriptive statistics with comparative testing and regression modeling. In simple terms, the researchers compared patients who successfully completed treatment with those who did not, then identified which factors were most strongly associated with failure.
The study considered a wide range of variables, including:
- Demographic factors such as age, gender, and ethnicity
- Socioeconomic status, particularly employment
- Clinical conditions, including diabetes and HIV/AIDS
- Treatment-related factors such as drug side effects, regimen type, and medication adherence
Key Findings: More Than Half of Patients Fail Treatment
The results are striking: 55.4 percent of patients experienced treatment failure. This means that more than one in two individuals undergoing therapy for drug-resistant TB in Papua did not achieve a successful outcome.
Several factors emerged as statistically significant contributors to treatment failure:
In contrast, variables such as age, gender, ethnicity, diabetes, and prior TB treatment history showed no significant relationship with treatment outcomes.
HIV/AIDS Emerges as the Most Dominant Factor
Although not significant in initial comparisons, advanced statistical modeling revealed that HIV/AIDS co-infection is the most dominant factor influencing treatment failure.
Patients with both drug-resistant TB and HIV face a complex clinical situation. Their immune systems are severely compromised, making it harder to fight infection. In addition, they must manage multiple medications simultaneously, increasing the risk of drug interactions and side effects.
The researchers emphasize that this dual burden significantly reduces the likelihood of successful treatment. As noted by Hasmi from Cenderawasih University, co-infected patients face “a much higher risk due to weakened immunity and the complexity of combined therapies,” highlighting the need for integrated TB-HIV care systems.
Why Adherence Matters Most
The study reinforces a critical insight: treatment adherence is the single most controllable factor in improving outcomes.
Drug-resistant TB therapy is demanding. Patients must take multiple medications daily for months or even years. Side effects such as nausea, fatigue, and neurological symptoms can discourage continued use. Without strong monitoring and support systems, many patients discontinue treatment prematurely.
The data show that nearly all patients who were non-adherent ultimately failed treatment. This finding positions adherence not just as a contributing factor, but as a central pillar of TB control.
Implications for Policy and Healthcare Practice
The findings from Cenderawasih University have direct implications for public health policy in Indonesia and similar high-burden regions.
To improve treatment success rates, healthcare systems must:
- Strengthen patient monitoring and adherence programs
- Provide early management of drug side effects
- Integrate TB and HIV services for co-infected patients
- Expand access to shorter, more tolerable treatment regimens
- Address socioeconomic barriers, including unemployment and access to care
Shorter treatment regimens, such as newer oral therapies lasting around six months, may offer a promising alternative. These approaches can reduce patient burden and improve adherence, ultimately increasing success rates.
Author Profile
- Yulpriati Kalua, S.KM., M.Kes – Master of Public Health graduate, Cenderawasih University; specialization in epidemiology and infectious diseases
- Hasmi, S.KM., M.Kes – Lecturer at the Faculty of Public Health, Cenderawasih University; expert in epidemiology and public health research
- Sarce Makaba, S.KM., M.Kes – Public health academic focusing on community health
- Arius Togodly, S.KM., M.Kes – Researcher in public health systems
- Novita Medyati, S.KM., M.Kes – Lecturer and researcher in health promotion
- RoRosmin Mariati Tingginehe, S.KM., M.Kes – Public health researcher specializing in infectious disease control
All authors are affiliated with the Faculty of Public Health, Cenderawasih University, Jayapura, Indonesia.
Source
This study highlights a critical reality: tackling drug-resistant tuberculosis requires more than medical treatment alone. Without strong adherence support and integrated care for patients with HIV, efforts to control TB in Indonesia may continue to fall short.
0 Komentar